ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

ISA Pharmaceuticals announces CervISA publication